BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 21, 2019 at 10:12 AM.

  1. #1 cafead, May 21, 2019 at 10:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via It was designed to be the oral fix for hereditary angioedema (HAE) — a rare, potentially life-threatening genetic disorder — but BioCryst Pharmaceutical’s experimental capsule has underwhelmed in a pivotal late-stage study, despite meeting the primary endpoint.

    article source
     
    Quote

Reply to Thread